News & Events

GenoID took part at WHO HPV LabNet Study

On Mar 13, 2009

The study found the GenoID Full Spectrum genotyping assay proficient for detection of HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66. The aim was to find manufacturers of HPV typing reagents worldwide who meet the requirements of producing assays with optimal sensitivity and specificity for WHO to apply in developing countries.

The WHO HPV LabNet was created to “contribute to improving quality of laboratory services for effective surveillance and monitoring of HPV vaccination impact, through enhanced, state-of-the-art laboratory support.”  WHO has the process of developing and validating international biologic standards for HPV DNA and serology testing well underway.  The LabNet identified assays with optimal sensitivity and specificity that will be most amenable to inter-laboratory standardization in the variety of conditions encountered internationally.

Expert consultants to WHO recommended that WHO should pursue and negotiate access to reliable and affordable HPV kits for long term use in the global HPV LabNet to sustain HPV surveillance in developing countries. 

As a result, WHO was seeking partnerships with manufacturers of HPV typing reagents and assays to assure a supply of standardized affordable reagents and assays for implementation world-wide.

WHO initiated these activities as part of a Bill and Melinda Gates Foundation funded project, contributed by a group of collaborating institutions working in partnership, which includes PATH in Seattle, Harvard University in Boston, IARC (International Agency for Research on Cancer) in Lyon, ICO (Institut Català d’Oncologia) in Barcelona and WHO in Geneva.